We are live on ! Find out more
PHIO icon

Phio Pharmaceuticals
PHIO

10 hedge funds and large institutions have $213K invested in Phio Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.12% less ownership

Funds ownership: 5.33% → 4.21% (-1.1%)

29% less funds holding

Funds holding: 14 → 10 (-4)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

88% less capital inflows, than outflows

Capital inflows: $10.9K | Capital outflows: $88.9K

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 6

Holders
10
Holders Change
-4
Holders Change %
-28.57%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$10.9K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$30.2K
2
Renaissance Technologies
Renaissance Technologies
New York
-$22.3K
3
Virtu Financial
Virtu Financial
New York
-$11K
4
HRT Financial
HRT Financial
New York
-$10K
5
E
Ergoteles
New York
-$7K

PHIO Hedge Fund Activity: Q4 2022 in Review

10 of the 6,242 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2022, worth a combined $213K — down 49% from $415K a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of PHIO and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $10.9K. The largest seller was Vanguard Group, cutting an estimated $30.2K.

  • 10 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2022, down from 14 in Q3 2022.
  • Funds reported $213K of Phio Pharmaceuticals stock for Q4 2022, down 49% quarter-over-quarter.
  • 1 fund opened new Phio Pharmaceuticals positions in Q4 2022 and 5 closed out, a net change of -4 holders.
  • The largest Phio Pharmaceuticals buyer in Q4 2022 was UBS Group, an estimated $10.9K added.
  • The largest Phio Pharmaceuticals seller in Q4 2022 was Vanguard Group, an estimated $30.2K sold.

Based on aggregated 13F filings for Q4 2022.